Working… Menu

Pertussis (Tdap) Vaccination in Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01698346
Recruitment Status : Completed
First Posted : October 3, 2012
Last Update Posted : October 24, 2019
National Institute of Hygiene and Epidemiology, Vietnam
Information provided by (Responsible Party):
Elke Leuridan, MD, PhD, Universiteit Antwerpen

Brief Summary:
Despite good vaccination coverage, included in national immunization programs in developed countries, the number of reported pertussis cases is rising, also in very young infants. Current immunization strategies fail to protect infants too young to be immunized with the licensed vaccine. Different strategies are possible to close the gap of susceptibility between the loss of maternal antibodies and protection by vaccination. The main aim of the present study is to measure the influence of an adult pertussis booster in pregnant women, on the titer and duration of maternal antibodies in their infants. Early humoral immunity will be assessed and the influence on vaccine response of the infant measured. The present study offers the opportunity to have new insights in neonatal immunological mechanisms against pertussis and a better understanding in strategies to protect infants against pertussis.

Condition or disease Intervention/treatment Phase
Pertussis Pregnancy Biological: Pertussis vaccine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 99 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants
Study Start Date : February 2012
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Whooping Cough

Arm Intervention/treatment
No Intervention: control
50 unvaccinated pregnant women
Active Comparator: Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)
50 pregnant women vaccinated with pertussis vaccine
Biological: Pertussis vaccine
Vaccination during pregnancy with a pertussis containing vaccine
Other Name: Boostrix®, GSK Biologicals, Rixensart

Primary Outcome Measures :
  1. Does vaccination of pregnant women with a combined vaccine Tetanus, diphtheria and acellular pertussis (Tdap), induce sufficiently high maternal antibody concentration in the newborns infants to possibly protect them until their own vaccination starts [ Time Frame: 16 months ]
    1. What are the concentrations of IgG against Pertussis Toxin (anti-PT), Filamentous Haemagglutinin (anti-FHA), Fimbriae (anti-Fim) and pertactin (anti-PRN):

      1. in women during pregnancy and at delivery after vaccination with TdaP
      2. in children at birth (cord), before starting vaccination (week 8), one month after primary course of three doses (week 20) and before and after the fourth pertussis vaccine dose (at month 15 and 16)
    2. What are the concentrations of anti-tetanus and anti-diphtheria IgG antibodies at all mentioned time points, to evaluate interference when administering several antigens and to evaluate the influence of maternal antibodies on vaccine response to tetanus and diphtheria in infants

Secondary Outcome Measures :
  1. Vaccine associated (Severe) Adverse Events ((S)AE) in pregnant women and children during the study time [ Time Frame: 16 months ]
    Vaccine associated (Severe) Adverse Events ((S)AE) in pregnant women and children during the study time

  2. Infant growth measurement at all time points [ Time Frame: 16 months ]
    Infant growth measurement at all time points

  3. Assessment of pneumococcal immune response in infants whose mothers received Tdap vaccination during pregnancy [ Time Frame: 12 months ]
    The present trial on pertussis vaccination during pregnancy, offers the opportunity to add evidence for a possible blunting effect of infant immune responses to pneumococcal infant vaccination after maternal Tdap vaccination. Pneumococcal antibodies will be measured in serum samples taken from infants after a primary series of 2 pneumococcal vaccine doses (2 and 4 months of age) and after a third vaccine dose (at 12 months of age). Infants are born from either vaccinated or unvaccinated mothers.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women aged 18-35 years
  • Willing to be immunized during pregnancy OR
  • Received already a pertussis vaccination during pregnancy, as advised by gynaecologist or general practitioner.
  • Age matched controls will be identified in the same time period in the recruiting hospital.
  • Availability for follow-up visits and phone call access through 16 months following delivery
  • Willing to have infant immunized with hexavalent vaccine at 8.12 and 16 weeks and 15 months of age (= normal Belgian schedule) with pediatrician, the general practitioner or at the Centre for the Evaluation of Vaccination.
  • In the 18th-32nd week of a pregnancy at low risk for complications as determined by the obstetrician

Exclusion Criteria:Women:

  • Serious underlying medical condition
  • History of a febrile illness (>= 38° Celsius) within the past 72 hours before injection
  • Previous severe reaction to any vaccine
  • Receipt of tetanus-diphtheria toxoid immunization within the past 1 month
  • Receipt of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap) immunization in the last 10 years
  • Receipt of a vaccine, blood product (excluding Rhogam) or experimental medicine within the 4 weeks prior to injection through 4 weeks following injection
  • Receipt of or plans to receive influenza vaccine within the 4weeks prior to or following injection. One month interval should be respected in order to evaluate eventual Adverse events following one of both vaccines (fever, local symptoms).
  • High risk for serious obstetrical complication
  • Anything in the opinion of the investigator that would put the participant at risk.

Exclusion criteria for the offspring:

  • Serious underlying medical condition
  • No signed informed consent by both parents
  • Severe reactions to any vaccine
  • Anything in the opinion of the investigator that would put the participant at risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01698346

Layout table for location information
Centre for the Evaluation of Vaccination
Antwerp, Belgium, 2610
National Institute of Hygien and Epidemiology
Hanoi, Vietnam, 10000
Sponsors and Collaborators
Universiteit Antwerpen
National Institute of Hygiene and Epidemiology, Vietnam
Layout table for investigator information
Principal Investigator: Elke Leuridan, MD, PhD Universiteit Antwerpen
Principal Investigator: Thu Ha Thi Hoang, MD PhD National Institute for Hygiene and Epidemiology
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Elke Leuridan, MD, PhD, MD, PhD, Universiteit Antwerpen Identifier: NCT01698346    
Other Study ID Numbers: cev001
2011-001936-45 ( EudraCT Number )
First Posted: October 3, 2012    Key Record Dates
Last Update Posted: October 24, 2019
Last Verified: October 2019
Keywords provided by Elke Leuridan, MD, PhD, Universiteit Antwerpen:
Additional relevant MeSH terms:
Layout table for MeSH terms
Whooping Cough
Bordetella Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Respiratory Tract Infections
Respiratory Tract Diseases